Mechanisms of Resistance to Hypomethylating Agents And BCL-2 inhibitors

DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes

(2021) Kensuke Kayamori et al.   Blood Advances

Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine

(2021) Ralf Buettner et al.   Journal of Hematology & Oncology

Myelodysplastic Syndromes: A New Decade

(2021) Virginia O. Volpe et al.   Clinical Lymphoma Myeloma & Leukemia

Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes.

(2021) Amer Methqal Zeidan et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges

(2020) Nicholas J. Short et al.   Cancer Discovery

Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network

(2020) Xiaorong Gu et al.   LEUKEMIA

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

(2020) Courtney D. DiNardo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells

(2020) Courtney L. Jones et al.   Cell Stem Cell

Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3 mimetic resistance in lymphomas

(2020) Scott Boiko et al.   BLOOD

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia

(2019) Eugen Tausch et al.   HAEMATOLOGICA

Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment

(2019) Xufeng Chen et al.   Cancer Discovery

Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma

(2019) Piers Blombery et al.   BRITISH JOURNAL OF HAEMATOLOGY

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

(2019) Thomas Oellerich et al.   Nature Communications

Global Interactome Mapping of Mitochondrial Intermembrane Space Proteases Identifies a Novel Function for HTRA2

(2019) Aaron Botham et al.   PROTEOMICS

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

(2018) Ibrahim Aldoss et al.   HAEMATOLOGICA

RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia

(2018) Jason X. Cheng et al.   Nature Communications

Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia

(2018) Ibrahim Aldoss et al.   HAEMATOLOGICA

A Novel MCL-1 Inhibitor Combined with Venetoclax Rescues Venetoclax Resistant Acute Myelogenous Leukemia

(2018) Haley E. Ramsey et al.   Cancer Discovery

Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells

(2018) Courtney L. Jones et al.   CANCER CELL

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia

(2017) Valérie Vidal et al.   Oncotarget

Finally, An Apoptosis-Targeting Therapeutic for Cancer

(2016) C. M. Croce et al.   CANCER RESEARCH

Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia

(2016) David B. Sykes et al.   CELL

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

(2016) Catherine C. Coombs et al.   HAEMATOLOGICA

SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia

(2016) Constanze Schneider et al.   NATURE MEDICINE

Epigenetic control of adult stem cell function

(2016) Alexandra Avgustinova et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells

(2016) Juraj Bodo et al.   Oncotarget

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

(2016) Catherine C. Coombs et al.   HAEMATOLOGICA

Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients

(2015) S Jilg et al.   LEUKEMIA

The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome

(2015) Ping Wu et al.   LEUKEMIA RESEARCH

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

(2015) Y. Xiao et al.   MOLECULAR CANCER THERAPEUTICS

CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer

(2015) Melania Zauri et al.   NATURE

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

(2015) J D Leverson et al.   Cell Death & Disease

Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

(2015) D C Phillips et al.   Blood Cancer Journal

BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients

(2015) Thomas Cluzeau et al.   Oncotarget

TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients

(2014) R. Bejar et al.   BLOOD

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

(2014) V. Fresquet et al.   BLOOD

BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells

(2013) Eleni D. Lagadinou et al.   Cell Stem Cell

Mechanisms of resistance to azacitidine in human leukemia cell lines

(2013) Piyanuch Sripayap et al.   EXPERIMENTAL HEMATOLOGY

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

(2013) F Traina et al.   LEUKEMIA

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Aicardi-Goutières Syndrome Gene and HIV-1 Restriction Factor SAMHD1 Is a dGTP-regulated Deoxynucleotide Triphosphohydrolase

(2011) Rebecca D. Powell et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

(2011) M J Walter et al.   LEUKEMIA

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias

(2011) R Itzykson et al.   LEUKEMIA

HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase

(2011) David C. Goldstone et al.   NATURE

The Intermembrane Space of Mitochondria

(2010) Johannes M. Herrmann et al.   ANTIOXIDANTS & REDOX SIGNALING

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines

(2008) T. Qin et al.   BLOOD

Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells

(2008) Eric I. Zimmerman et al.   FEBS LETTERS